Journal
JOURNAL OF INTERNAL MEDICINE
Volume 267, Issue 3, Pages 260-277Publisher
WILEY
DOI: 10.1111/j.1365-2796.2009.02207.x
Keywords
autoimmune diseases; CD20; immunotherapy; monoclonal antibodies; target antigen
Categories
Funding
- University of Bari
- Italian Association for Cancer (AIRC), Milan, Italy
Ask authors/readers for more resources
The B lymphocyte-associated antigen CD20 is becoming an important immunotherapy target for autoimmune diseases, although its biological function has not been defined. Besides rheumatoid arthritis, growing experience with B cell-depleting therapy indicates that it may be effective in Sjogren's syndrome, dermatomyositis-polymyositis, systemic lupus erythematosus and some types of vasculitides. However, controlled clinical trials are still lacking for some of these indications. Infection has not been seen as a major limitation to this therapy, but reports of progressive multifocal leukoencephalopathy in an extremely small number of patients are of concern. Here, we review the therapeutic actions of anti-CD20 antibodies, and the recent and ongoing clinical trials with CD20-depleting therapy in autoimmune diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available